Knowledge of HIV Postexposure Prophylaxis in a Population of HIV-Positive Outpatients: Results of a French National Survey

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 4, 2004, Pages 393-400

  Rey, Dominique ^a,b   Marimoutou, Catherine ^a,b   Bouhnik, Anne Deborah ^a   Dray Spira, Rosemary ^b   Lert, France ^b   Obadia, Yolande ^a,b  

^a OBSERVATOIRE RÉGIONAL DE LA SANTÉ PROVENCE ALPES CÔTE D AZUR   (France)

^b INSERM   (France)

Author keywords

HIV postexposure prophylaxis; HIV positive individuals; Knowledge and behaviors; Nonoccupational exposure

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; VIRUS RNA;

ADULT; AGE; ARTICLE; ATTITUDE; EDUCATION; FEMALE; FRANCE; HOUSING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OUTPATIENT; PRIORITY JOURNAL; SECONDARY PREVENTION; SEXUAL BEHAVIOR;

ADULT; ANTI-HIV AGENTS; ANTI-RETROVIRAL AGENTS; CROSS-SECTIONAL STUDIES; DATA COLLECTION; FEMALE; FRANCE; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED;

EID: 1542409143     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200404010-00009     Document Type: Article

References (37)

1. th, 1995. Information note DGS/DH/DRT no. 81.
2. Cardo D, Culver D, Ciesielski C, et al. A case-control study of HIV sero-conversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485-1490.
3. Hughes MD, Johnson VA, Hirsch MS, et al. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response. ACTG 241 Protocol Virology Substudy Team. Ann Intern Med. 1997;126:929-938.
4. Mocroft A, Gill MJ, Davidson W, et al. Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor. AIDS. 1998;12:2161-2167.
5. Hogg RS, Rhone SA, Yip B, et al. Antiviral effect of double and triple drug combinations amongst HIV-infected adults: lessons from the implementation of viral load-driven antiretroviral therapy. AIDS. 1998;12:279-284.
6. Grob PM, Cao Y, Muchmore E, et al. Prophylaxis against VIH-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nat Med. 1997;3:665-670.
7. Otten RA, Smith DK, Adams DR, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000; 74:9771-9775.
8. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med. 1994;331:1173-1180.
9. Wade NA, Birkhead GS, Warren BL, et al. Abbreviated regimens of zidovudine prophylaxis and perinatal transmission of the human immunodeficiency virus. N Engl J Med. 1998;339:1409-1414.
10. Katz MH, Gerberding JL. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection drug use. N Engl J Med. 1997;336:1097-1100.
11. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS. 2000;14:1864-1866.
12. Low-Beer S, Weber A, Bartholomew K, et al. A reality check: the cost of making post-exposure prophylaxis available to gay and bisexual men at high sexual risk. AIDS. 2000;14:325-326.
13. Pinkerton SD, Holtgrave DR, Bloom FR. Cost-effectiveness of postexposure prophylaxis following sexual exposure to HIV. AIDS. 1998;12: 1067-1078.
14. th 1998 relating to the recommendations of implementation of a antiretroviral treatment after exposure to the risk of transmission of HIV [in French].
15. Delfraissy JF, and French expert group. Accidental exposure to HIV infection. In: Recommendations for Care and Management of HIV Infected Persons [in French]. Health Ministry. Paris: Flammarion; 1999:197-214.
16. Lot F, Larsen C, Basselier B, et al. Evaluation of prophylactic treatments after accidental exposure to HIV infection: France July 1999-December 2001 [in French]. Bull Epidemiol Hebdomadaire. 2002;36:173-175.
17. Laporte A, Jourdan N, Bouvet E, et al. Post exposure prophylaxis after non-occupational HIV exposure: impact of recommendations on physicians' experiences and attitudes. AIDS. 2002;16:397-405.
18. Gremy I, Beltzer N, Vongmany N, et al. Knowledge, Attitudes, Behaviours and Practices Towards HIV/AIDS in France: Evolutions 1992-1994-1998-2001 [in French]. Paris: Observatoire Régional de la Santé Ile de France; 2001.
19. Phillips AN, Grabar S, Tassie JM, et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS. 1999;13:2075-2082.
20. Waldo CR, Stall RD, Coates TJ. Is offering post-exposure prevention for sexual exposures to HIV related to sexual risk behavior in gay men? AIDS. 2000;14:1035-1039.
21. Kalichman SC, Benotsch E, Suarez T, et al. Health literacy and health-related knowledge among persons living with HIV-Aids. Am J Prev Med. 2000;18:325-331.
22. Jourdan N, Martin K, Pillonel J, et al. Evolution de l'expérience des médecins hospitaliers concernant la prophylaxie après exposition non professionnelle au VIH entre 1997 et 1999. Bull Epidemiol Hebdomadaire. 2000;50:223-224.
23. Schiltz MA, Sandfort TGM. HIV-positive people risk and sexual behaviour. Soc Sci Med. 2000;50:1571-1588.
24. Reilly T, Woo G. Predictors of high-risk sexual behavior among people living with HIV/AIDS. AIDS Behav. 2001;5:205-217.
25. Ekstrand M, Stall R, Paul J, et al. Gay men report high rates of unprotected anal sex with partners of unknown or discordant HIV status. AIDS. 1999; 13:1525-1533.
26. Van der Straten A, Gomez CA, Saul J, et al. Sexual risk behaviors among heterosexual HIV serodiscordant couples in the era of post-exposure prevention and viral suppressive therapy. AIDS. 2000;14:F47-F54.
27. Buchacz K, van der Straten A, Saul J, et al. Sociodemographic, behavioral, and clinical correlates of inconsistent condom use in HIV-serodiscordant heterosexual couples. J Acquir Immune Defic Syndr. 2001; 28:289-297.
28. Gollub E, Rey D, Obadia Y, et al. Gender differences in risk behaviors among HIV+ persons with an IDU history: the link between partner characteristics and women's higher drug-sex risks. Sex Transm Dis. 1998;9: 483-488.
29. Moore J, Hamburger ME, Vlahov D, et al. Longitudinal study of condom use patterns among women with or at risk for HIV. AIDS Behav. 2001;5: 263-273.
30. Hoff C, Stall R, Paul J, et al. Differences in sexual behavior among HIV discordant and concordant gay men in primary relationships. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14:72-78.
31. Dolezal C, Meyer-Bahlburg HF, Liu X, et al. Longitudinal changes in sexual risk behavior among HIV+ and HIV- male injecting drug users. Am J Drug Alcohol Abuse. 1999;25:281-303.
32. Eich-Hochli D, Niklowitz MW, Clement U, et al. Predictors of unprotected sexual contacts in HIV-infected persons in Switzerland. Arch Sex Behav. 1998;27:77-90.
33. Latkin CA, Knowlton AR, Forman VL, et al. Injection drug users' disclosure of HIV seropositive status to network members. AIDS Behav. 2001; 5:297-305.
34. Nadal J, Bourdillon F, Haury B, et al. Les principales caractéristiques de la file active hospitalière des personnes atteintes d'infection à VIH en France en 1996 [in French]. Bull Epidemiol Hebdomadaire. 1997;23: 107-108.
35. Darke S. Self report among injecting drug users: a review. Drug Alcohol Depend. 1998;51:253-263.
36. McElrath K, Chitwood DD, Griffin DK, et al. The consistency of self-reported HIV risk behavior among injection drug users. Am J Public Health. 1994;84:1965-1970.
37. Suarez TP, Kelly JA, Pinkerton SD, et al. Influence of a partner's HIV serostatus, use of highly active antiretroviral therapy, and viral load on perceptions of sexual risk behavior in a community sample of men who have sex with men. J Acquir Immune Defic Syndr. 2001;28:471-477.